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Background: In contrast to olanzapine, ziprasidone has been reported to cause minimal or no weight gain. This study
aimed to compare the effects of ziprasidone and olanzapine on weight, body composition, appetite, resting energy
expenditure, substrate oxidation, and metabolic parameters in adults with schizophrenia or other psychotic disorders.
Methods: Twenty adults with schizophrenia or other psychotic disorders were randomized 1:1 to ziprasidone
20–160 mg/day or olanzapine 5–20 mg/day for 12 weeks. The mean doses during the 12-week study period were 109
(range: 65–140) mg/day for ziprasidone and 11.6(range: 8.2–15.5) mg/day for olanzapine. Body weight, appetite, body
composition, resting energy expenditure, and metabolic parameters were measured before and after drug treatment.
Outcome measurements before and after medication were compared, and ziprasidone- and olanzapine-treated
patients were compared.
Results: After 12 weeks, olanzapine-treated patients showed significant weight gain, particularly fat gain, with
increased low density lipoprotein-cholesterol and decreased high density lipoprotein-cholesterol concentrations. In
contrast, ziprasidone-treated patients showed no significant weight gain with increased high density
lipoprotein-cholesterol concentration.
Conclusions: Ziprasidone was associated with a lower propensity for weight gain and central fat deposition than
olanzapine. Studies in larger patient samples are required to confirm these results.
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Weight gain is a common adverse effect associated with
atypical antipsychotic drug treatment of patients with
psychotic disorders [1-6]. Among these atypical anti-
psychotic drugs, clozapine and olanzapine are associated
with the greatest weight gain [1,6]. This weight gain is a
frequent cause of poor adherence to antipsychotic medica-
tions, as well as increased risks of metabolic complications,
including obesity, dyslipidemia, glucose intolerance, and
diabetes mellitus [7-11].
In contrast to other atypical antipsychotic agents,
ziprasidone, a novel antipsychotic agent with a unique
receptor-binding profile, has been reported to cause* Correspondence: jphong@amc.seoul.kr
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reproduction in any medium, provided the orminimal or no weight gain [2,12-17]. This drug also has
other significant metabolic advantages, including decreased
risks of developing insulin resistance and dyslipidemia,
compared with other atypical antipsychotics [14,18-20].
Several preclinical and clinical studies have provided
insights into the mechanism underlying antipsychotic-
induced weight gain. To date, increased appetite, sedation,
and hyperprolactinemia have all been associated with
antipsychotic-induced weight gain [21-24]. However, their
precise mechanism has yet to be elucidated. Body weight
is determined by the balance between caloric intake and
energy expenditure, with a positive energy balance indu-
cing fat deposition and weight gain. Several studies have
therefore investigated the effects of atypical antipsychotic
drugs, in particular olanzapine, on body composition and
energy balance. Our recent preclinical study suggested
that a 7-week treatment regimen of ziprasidone induced a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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increasing resting energy expenditure without decreasing
food intake [25].
Although central fat deposition and dyslipidemia have
been consistently reported in patients taking olanzapine
[1,18,26-28], studies of the effects of olanzapine on resting
energy expenditure [27,29,30] have yielded inconsistent
results. Moreover, in contrast to the many studies of
the metabolic effects of olanzapine, there have been few
studies in humans on the effects of ziprasidone on body
composition and energy expenditure.
Comprehensive comparisons of the metabolic effects of
ziprasidone, the antipsychotic drug with a low propensity
for weight gain, and olanzapine, a drug with a high pro-
pensity for weight gain, may be helpful in elucidating
the mechanisms underlying weight gain and metabolic
changes associated with antipsychotic drug use. We there-
fore compared the effects of 12 weeks of treatment with
ziprasidone or olanzapine on weight, body composition,
appetite, resting energy expenditure, substrate oxidation,
and metabolic parameters in adults with schizophrenia and
or other psychotic disorders.Methods
Subjects
Adult patients who visited the Asan Medical Center
experiencing a new onset psychotic episode (either first
onset or a new onset discontinuation-related episode)
were asked to participate in an investigation of the meta-
bolic impact of olanzapine and ziprasidone. Patients were
included if 1) they were 18–65 years of age, 2) had been
diagnosed by a psychiatrist with a brief psychotic disorder,
schizophreniform disorder, schizophrenia, or schizoaffective
disorder according to Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) criteria, and 3)
had no other active illness. Patients were excluded if
they 1) had a comorbid alcohol or drug abuse disorder,
2) were pregnant or lactating, 3) required treatment with
medications other than lorazepam, clonazepam, zolpidem,
benztropine, or propranolol for any medical or other
psychiatric condition, or 4) had been administered any
antipsychotic drugs during the previous three months.
The study was approved by the institutional review board
(IRB) for human subjects at the Asan Medical Center, and
all subjects provided written informed consent.Procedures
The screening assessment included a full psychiatric
history, a medical history, demographic data, and physical
examination. We used the Korean version of the Structured
Clinical Interview for DSM-IV [31] to determine psychiatric
diagnosis and eligibility for this study. Following screen-
ing and enrollment, patients were randomized to receiveziprasidone or olanzapine for 12 weeks. Randomization
was stratified by sex and age.
Within 14 days of screening, subjects were admitted to
a psychiatric ward of Asan Medical Center for at least
24-hours. Before starting medication, subjects’ body
weight, height and waist and hip circumference were
measured; we also assessed their body composition,
resting energy expenditure, and respiratory quotient.
Fasting blood samples were taken for assays and
appetite was measured. We utilized the Korean ver-
sion of the Positive and Negative Syndrome Scale
(PANSS) [32] to assess the severity of psychiatric symp-
toms in each patient.
Patients were subsequently started on 40 mg/day
ziprasidone or 10 mg/day olanzapine. Dosage was adjusted
depending on each patient's symptom severity and drug
tolerability. Throughout the study period, the doses of
ziprasidone ranged between 20 and 160 mg/day and those
of olanzapine between 5 and 20 mg/day. The mean daily
doses during the 12-week study period were 109(range:
65–140) mg/day for ziprasidone and 11.6(range: 8.2–15.5)
mg/day for olanzapine.
After six weeks of treatment, subjects came to the
psychiatry outpatient department of the Asan Medical
Center. At this time, adverse events and medication use
were assessed, and weight, height and waist and hip cir-
cumference were measured.
After 12 weeks of treatment, subjects were admitted as
inpatients to the Asan Medical Center for 24 hours. In
addition to the same assessments taken at 4 weeks, we
assessed body composition, resting energy expenditure,
respiratory quotient, PANSS, and appetite, and fasting
blood samples were taken for assays.
Outcome measurements
During their first and last inpatient visits, subjects were
fasted for 12 h, starting the evening before, with minimum
physical activity on the test day, and anthropometric
measurements and blood samples taken upon awakening.
Measurements taken during 6-week outpatient visits were
taken at various times of the day.
Each subject completed questionnaires to assess hunger,
fullness, desire to eat and prospective food consumption
using subject appetite scores [33]. Ratings were made on a
10 cm Visual Analog Scale with words anchored at each
end, expressing the most positive (e.g. good, pleasant) and
most negative (e.g. bad, unpleasant) ratings. Mean appetite
scores were calculated, with higher scores indicating a
greater subjective appetite.
Body weight was measured with subjects wearing light
clothing on a digital scale that was calibrated monthly.
Height was assessed using a wall-mounted stadiometer.
Waist circumference was measured at the umbilicus and
hip circumference at the fullest part of the hips.
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and muscle mass) was assessed by bio- electrical imped-
ance using an InBody 720 body composition analyzer
(BioSpace).
Substrate utilization (respiratory quotient) and rest-
ing energy expenditure were determined by indirect
calorimetry with a MedGraphics CPX Ultima (Medical
Graphics Corp, St Paul, MN) respiratory system. Oxy-
gen consumption and carbon dioxide production were
measured at 30-second intervals over 20 minutes at
standard temperature, pressure, and humidity. Resting
energy expenditure was calculated using the equation:
Expenditure = (3.815 + 1.232 x VO2/VCO2) x VO2.
Standard laboratory methods were used to determine
fasting concentrations of glucose, insulin, total cholesterol,
high density lipoprotein cholesterol (HDL-C), low density
lipoprotein cholesterol (LDL-C), triglycerides, C-peptide
and prolactin.
Statistical analysis
The study’s main outcome measures were changes in body
weight, appetite, body composition, energy expenditure,
respiratory quotient, and metabolic parameters. Due to the
skewed distribution of outcome variables and small sample
size, nonparametric statistical calculations were performed.
Thus, median rather than mean changes were calculated.
The Wilcoxon signed rank test was used to test whether
outcome measures at last observation were significantly
different from initial observations in each group. The
Kruskal-Wallis H test was used to test whether the
ziprasidone and olanzapine groups differed in percent
changes of outcome measures from first to last observa-
tions. All statistical analyses were performed using SPSS
(version 12.0; SPSS Inc., Chicago, IL), with statistical sig-
nificance defined as an alpha level < 0.05. For the outcome
variables, of which baselie measurements were significantly
different between groups, R 2.14.0, Package [fANCOVA]
was used to test whether the ziprasidone and olanzapine
groups differed in absolute changes of outcome measures
after adjustment for the baseline measures.
Results
Patient demographics
Each group consisted of 10 subjects (five males and five
females), with similar median ages in the ziprasidone
(34.50 years, interquartile range [IQR] = 26.25–40.25 years)
and olanzapine (31.50 years, IQR = 26.50–41.25 years)
groups (p > 0.99) and similar median baseline symptom
severity, as measured by the PANSS, for patients treated
with ziprasidone (67.50, IQR = 62.25–75.25) and olanzapine
(82.00, IQR = 64.25–86.25) (p = 0.161). Median PANSS
scores after 12 weeks of treatment were also similar in the
ziprasidone (53.00, IQR = 42.00–78.75) and olanzapine
(60.00, IQR = 53.00–67.00) groups (p = 0.677). Baselinemeasurements of outcome variables were not signifi-
cantly different between groups (p > 0.10), except rest-
ing energy expenditure normalized to lean body mass
(LBM) (p = 0.041).
Body weight, appetite, and body composition
Table 1 showed that body weight, body mass index, and
waist to hip ratio increased significantly in patients treated
with olanzapine, but not ziprasidone. After 12 weeks, the
median increase in body weight in the olanzapine group
was 6.25 kg (IQR = 5.70–6.90 kg), representing an increase
of 10.35% from first to last observation (p = 0.005), whereas
the median weight gain in the ziprasidone group was
2.00 kg (IQR = 0.25–5.93 kg), representing an increase
of 3.43% from first to last observation (p = 0.168). BMI
increased significantly in olanzapine-treated patients,
with a median increase of 2.10 kg/m2 or 10.93% of initial
BMI (p = 0.005), but did not change significantly in the
ziprasidone group, with a median increase of 0.80 kg/m2
or 4.09% of BMI (p = 0.139). Waist to hip ratio increased
significantly in the olanzapine (median 0.03 or 3.62%,
p = 0.005), but not in the ziprasidone (median 0.00%) group.
The Kruskal-Wallis H test showed that, after 12 weeks of
treatment, the percent changes in body weight (p = 0.016),
BMI (p = 0.019), and waist to hip ratio (p = 0.004) were
significantly greater in patients treated with olanzapine
than with ziprasidone (Table 1). These between-group
differences in changes in body weight (p = 0.023), BMI
(p = 0.021), and waist to hip ratio (p = 0.009) were also
significant after 6 weeks.
Subjective appetite did not differ significantly before and
after treatment in both groups, but ziprasidone-treated pa-
tients tended to show a greater percent change in appetite
than olanzapine-treated patients (−20% vs. 0%, p = 0.059)
(Table 1).
As shown in Table 1, fat mass increased significantly in
the olanzapine group, with a median increase of 13.00 kg
or 31.57% of initial body fat (p = 0.017), but was not sig-
nificantly changed in the ziprasidone group, with a median
increase of 0.65 kg or 7.84% (p = 0.721). In contrast, LBM
and muscle mass increased significantly in the ziprasidone
group (p = 0.028 each), but not in the olanzapine group
(p = 0.074 each), despite the significant increase in total
body weight in the latter. The Kruskal-Wallis H test
showed that the percent change in fat mass was signifi-
cantly higher in olanzapine than in ziprasidone-treated
patients (31.57% vs. 7.84%, p = 0.049), but that percent
changes in LBM (3.78% vs. 3.05%, p = 0.821) and muscle
mass (0.90% vs. 3.01%, p = 0.762) were similar.
Energy expenditures
Table 2 showed that absolute 24-hour resting energy
expenditure, resting energy expenditure normalized to
LBM, and respiratory quotient were not significantly
Table 1 Body weight, body composition, and appetite of ziprasidone- and olanzapine-treated patients (n = 10 per group)
Ziprasidone start Ziprasidone end Olanzapine start Olanzapine end Ziprasidone change (%)a Olanzapine change (%)a
Measure Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pc
BW(kg) 58.75 (54.28, 61.68) 60.85 (56.40, 67.88) 0.168 57.70 (51.25, 65.90) 65.70 (56.73, 72.88) 0.005* 3.43 (0.61, 9.20) 10.35 (9.27, 14.65) 0.016*
BMI (kg/m2) 21.50 (19.20, 24.00) 22.35 (19.48, 25.18) 0.139 21.85 (17.90, 23.65) 23.95 (20.35, 26.53) 0.005* 4.09 (0.55, 10.20) 10.93 (9.02, 15.08) 0.019*
Waist to hip ratio 0.86 (0.83, 0.91) 0.84 (0.82, 0.94) 0.916 0.85 (0.81, 0.88) 0.87 (0.85, 0.93) 0.005* 0.00 (−0.01, 0.02) 3.62 (2.16, 5.10) 0.004*
LBM (kg) 44.65 (38.13, 48.30) 46.35 (42.48, 51.20) 0.028* 44.35 (40.23, 54.30) 47.70 (41.63, 54.25) 0.074 3.05 (1.36, 9.71) 3.78 (−2.41, 11.53) 0.821
Muscle mass (kg) 41.90 (35.80, 45.68) 43.55 (39.88, 49.00) 0.028* 41.75 (37.95, 51.55) 43.80 (39.20, 51.50) 0.074 3.01 (0.53, 9.67) 3.90 (−2.50, 7.40) 0.762
Fat mass (kg) 17.05 (7.58-21.88) 14.65 (8.40, 23.23) 0.721 13.00 (10.15, 15.73) 17.70 (12.05, 20.33) 0.017* 7.84 (−12.34, 28.88) 31.57 (20.15, 56.03) 0.049*
Appetite 5.00 (4.31, 6.44) 5.00 (3.38, 5.31) 0.212 5.00 (4.19, 5.25) 5.00 (4.69, 6.13) 0.399 −20.0 (−29.80, 5.00) 0.00 (−6.25, 39.34) 0.059
IQR Interquartile Range, BW Body Weight, BMI Body Mass Index, LBM, LBM.
a, posttreatment−baselineð Þbaseline * 100;
















Table 2 Energy expenditure and respiratory quotients of ziprasidone and olanzapine-treated patients (n = 10 per group)
Ziprasidone start Ziprasidone end Olanzapine start Olanzapine end Ziprasidone change (%)a Olanzapine change (%)a
Measure Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pc
Absolute REE
(kcal/24 hr)
1075.20 (1024.78, 1416.81) 1132.38 (1006.71, 1723.06) 0.678 1630.24 (1079.23, 1898.10) 1255.40 (1069.48, 1747.83) 0.241 1.41 (−11.98, 61.96) −5.27 (−33.37, 10.58) 0.369
REE normalized
to LBM (kcal/g)
18.29 (16.68, 22.39) 24.47 (22.48, 37.13) 0.011* 27.36 (19.91, 35.36) 27.60 (23.46, 34.85) 0.445 37.78 (18.36, 83.14) 17.17 (−17.47, 36.36) 0.072
Respiratory
Quotient
0.82 (0.76, 0.88) 0.84 (0.80, 0.92) 0.262 0.86 (0.81, 1.01) 0.87 (0.82, 0.92) 0.574 5.81 (−3.33, 14.40) −4.64 (−13.31, 13.27) 0.288
IQR Interquartile Range, REE Resting Energy Expenditure, LBM, LBM.
a, posttreatment−baselineð Þbaseline * 100;
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treated patients showed a significant increase in resting
energy expenditure normalized to LBM, 6.91 kcal/g or
37.78%, without significant changes in absolute 24-hour
resting energy expenditure and respiratory quotient. How-
ever, there were no statistically significant group-differences
in the percent changes in energy expenditure measures.
In addition, after adjusting for baseline resting energy
expenditure normalized to LBM that had been different
between two groups, there was no significant difference
in changes in resting energy expenditure normalized to
LBM between ziprasidone-treated and olanzapine-trated
patients (4.93 vs. 1.50, t = 4.98, p = 0.627).
Laboratory findings
Table 3 showed that median LDL-C (17.00 mg/dl, p = 0.017)
and prolactin (3.90 mg/dl, p = 0.028) concentrations
increased significantly in olanzapine-treated, but not
in ziprasidone-treated, patients. In contrast, median
total cholesterol (7.50 mg/dl, p = 0.021) and HDL-C
(4.00 mg/dl, p = 0.036) concentrations increased signifi-
cantly in the ziprasidone, but not in the olanzapine,
group. Other laboratory values, including glucose, insu-
lin, and C-peptide did not change significantly in either
group. The Kruskal-Wallis H test showed that the per-
cent change in HDL-C concentration was significantly
greater in the ziprasidone than in the olanzapine group
(7.36% vs. −13.24%, p = 0.008), but that the percent changes
of other laboratory values did not differ significantly
between these two groups.
Discussion
We have shown here that patients treated with olanzapine
for 12 weeks experienced significant weight gain, particu-
larly fat gain, with increased LDL-C and decreased HDL-C
concentrations, whereas patients treated with ziprasidone
for 12 weeks experienced a non-significant weight gain,
particularly muscle weight gain, with increased HDL-C
concentration. To our knowledge, this is the most compre-
hensive metabolic outcome study of ziprasidone treatment,
including resting energy expenditure and body compos-
ition, as well as anthropometric and metabolic parameters.
Weight gain was experienced by all but two subjects,
both in the ziprasidone group, who were receiving
80 mg/day and 120 mg/day ziprasidone, respectively. The
two subjects who experienced the greatest weight gain
(10 kg over 12 weeks) included one receiving 80 mg/day
ziprasidone and one receiving 10 mg/day olanzapine, the
median respective doses in these patients. We observed
no evidence of associations between weight gain and
drug dose. However, the study sample was too small to
determine such associations.
Consistent with previous results [26,27], we found that
the significant weight gain in the olanzapine group wasdue primarily to an increase in body fat, accounting for
about 61% of the total weight gain. Furthermore, the
increase in the waist to hip ratio of olanzapine treated
patients suggests central fat deposition. In contrast, the
non-significant weight gain observed in ziprasidone treated
patients was due primarily to an increase in muscle mass,
accounting for about 75% of the total weight gain.
The fat gain observed in olanzapine-treated patients
suggests that these subjects maintained a positive energy
balance and deposited this energy in the form of triglycer-
ides in adipose tissue. A positive energy indicates increased
caloric intake or decreased energy expenditure [34].
Although we did not directly measure the caloric intake of
these patients, we assessed their subjective appetite, which
was expected to be associated with caloric intake. Previous
studies have consistently reported that increased appetite
is a common adverse effect of olanzapine treatment
[26,28,29], but not of ziprasidone treatment [12,13,15,17].
Although we found that neither agent increased appetite
significantly, ziprasidone-treated patients showed a greater
decrease in appetite than olanzapine-treated patients,
suggesting that this difference in change in appetite may
have contributed, at least in part, to the lower propensity
toward weight gain with ziprasidone than with olanzapine.
Consistent with previous studies in rats [35-37] and
humans [26,27,29,30], olanzapine neither increases nor
decreases resting energy expenditure. To our knowledge,
no previous study has analyzed the effects of ziprasidone
on resting energy expenditure. Although resting energy
expenditure normalized to LBM increased significantly
after treatment of ziprasidone, there were no statistically
significant differences in the percent or absolute changes
in energy expenditure measures between ziprasidone- and
olanzapine- treated patients.
We measured respiratory quotient to determine whether
ziprasidone or olanzapine affects substrate oxidation. We
found that neither ziprasidone nor olanzapine affected
respiratory quotient. In contrast, others [27] have reported
an increase in respiratory quotient, indicating a shift in
nutrient utilization away from fatty acids toward carbohy-
drates, after 12 weeks of olanzapine therapy, suggesting
that this decrease in fatty acid oxidation may be associated
with olanzapine-induced fat deposition and weight gain.
Actually, the decision to utilize fatty acids or carbohydrates
as fuels is highly regulated and depends on numerous
exogenous and endogenous factors, including the level
of caloric intake, the composition of food eaten, the size
of glycogen stores, and the amount of adipose tissue
[38]. Since we did not measure the amount or pattern of
food intake, the interpretation of our results on respiratory
quotient is limited.
Atypical antipsychotics, particularly olanzapine, have
been associated with impaired glucose tolerance and
type 2 diabetes [8-10]. None of our subjects developed
Table 3 Fasting laboratory parameters of ziprasidone and olanzapine-treated patients (n = 10 per group)
Ziprasidone start Ziprasidone end Olanzapine start Olanzapine end Ziprasidone change (%)a Olanzapine change (%)a
Measure Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pc
Cholesterol (mg/dl) 153.50 (143.00, 175.00) 171.00 (154.00, 185.25) 0.021* 176.50 (154.40, 205.75) 200.00 (160.00, 223.50) 0.203 4.95 (1.99, 24.55) 15.39 (−7.49, 22.09) >0.99
Triglyceride (mg/dl) 89.00 (63.00, 112.75) 88.50 (81.00, 154.25) 0.114 73.50 (58.00, 106.50) 118.00 (71.50, 180.75) 0.086 30.35 (−3.72, 58.04) 62.54 (−3.08, 137.66) 0.290
HDL-C (mg/dl) 49.50 (44.00, 54.25) 58.50 (52.50, 61.50) 0.036* 59.00 (47.00, 65.25) 50.00 (46.75, 55.75) 0.092 7.36 (1.19, 29.55) −13.24 (−23.56 , -4.02) 0.008*
LDL-C (mg/dl) 85.00 (71.55, 104.95) 100.00 (81.50, 109.00) 0.144 106.00 (77.50, 115.00) 129.00 (116.50, 143.00) 0.043* 7.07 (−0.68, 19.31) 16.04 (3.76, 84.25) 0.347
Glucose (mg/dl) 90.50 (81.75, 95.50) 95.50 (86.75, 98.00) >0.99 89.50 (83.00, 96.50) 98.00 (87.75, 108.50) 0.241 −1.08 (−6.89, 6.69) 4.58 (−3.38, 17.92) 0.496
Insulin (IU/ml) 9.55 (5.58, 13.18) 6.30 (3.80, 10.35) 0.169 9.25 (5.85, 11.95) 6.75 (3.73, 10.50) 0.333 −25.46 (−47.37, 15.95) −27.35 (−59.38, 39.37) 0.705
C-peptide (ng/ml) 2.30 (1.15, 2.45) 1.95 (1.25, 2.25) 0.357 1.70 (1.65, 2.33) 2.15 (1.35, 3.23) 0.314 −11.01 (−14.13, 15.56) 8.06 (−18.20, 89.71) 0.273
Prolactin (ng/ml) 9.55 (5.58, 13.18) 7.35 (6.15, 43.30) 0.285 10.95 (7.18, 19.38) 19.10 (11.33, 28.10) 0.028* 31.40 (−45.21, 262.32) 28.06 (−8.06, 122.40) 0.880
IQR Interquartile Range, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol.
a, posttreatment−baselineð Þbaseline * 100;
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concentrations of fasting glucose, insulin, and C-peptide.
However, consistent with previous findings [18,27,28],
we found that olanzapine-treated patients exhibited ad-
verse changes in several metabolic parameters, including
tendencies for HDL-C and triglyceride concentrations to
decrease and significant increases in LDL-C and prolactin
concentrations. In contrast, ziprasidone-treated patients
showed a significant increase in HDL-C concentrations
and no changes in triglyceride, LDL-C, and prolactin
concentrations. The increased cholesterol concentration we
observed in ziprasidone-treated patients was not consistent
with previous results, reporting that ziprasidone had
favorable metabolic effects [14,18]. However, our compari-
son of ziprasidone- and olanzapine-treated patients showed
no between-group difference in percent change in choles-
terol concentrations.
We must interpret the present study's results in the
context of the following limitations. First, owing to our
small sample size, study findings should be considered
preliminary in nature and require careful interpretation.
Second, neither we nor the patients were blind to each
subject's medication. Therefore there is a possibility of
potential bias when we measured symptom severity by
the PANSS and the patients estimated their appetite.
However, most outcomes are obtained objectively from
physical measurement or laboratory assay, which may
not be biased due to no blindness. Finally, we did not
measure caloric intake and levels of physical activity,
and the use of sedatives was not controlled, all of which
may have influenced the metabolic outcomes.Conclusions
In conclusion, we found that ziprasidone was associated
with a lower propensity for weight gain and central fat
deposition than olanzapine. Additional studies, in larger
patient samples, as well as reliable measurements of food
intake and activity level, are needed.
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